NCT03120832 is a Phase 1 clinical trial of PAN-301-1 in Prostate Cancer, sponsored by Sensei Biotherapeutics, Inc..

Who is sponsoring NCT03120832?

NCT03120832 is sponsored by Sensei Biotherapeutics, Inc..

What drugs are being tested in NCT03120832?

Interventions in NCT03120832: PAN-301-1.

What condition does NCT03120832 study?

NCT03120832 studies Prostate Cancer.

Is NCT03120832 still recruiting?

NCT03120832 is currently completed. Last updated 15 October 2021.

Are results published for NCT03120832?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-10-15 · How we verify

NCT03120832

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients

Completed Phase 1 Results posted Last updated 15 October 2021

What this trial tests

Phase 1 trial testing PAN-301-1 in Prostate Cancer in 12 participants. Completed in 1 December 2018.

Timeline

1 December 2016

Primary endpoint
1 December 2018

1 December 2018

Quick facts

Lead sponsor	Sensei Biotherapeutics, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 December 2016
Primary completion	1 December 2018
Estimated completion	1 December 2018
Sites	4 locations across United States

Drugs / interventions tested

PAN-301-1 — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Sensei Biotherapeutics, Inc. — full company profile →

Who can join

Adults 21 to 85, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety Assessed by Development of Adverse Events and Dose-limiting Toxicity to Determine Maximum Tolerated Dose
Time frame: Through the 21 day interval after the first dose of vaccine

Sponsor's own description

This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose escalation schema every 21 days.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.
Ho W, Gao M, Li F, Li Z, et al · · 2021 · cited 176× · PMID 33458958 · DOI 10.1002/adhm.202001812
Nano toolbox in immune modulation and nanovaccines.
Azharuddin M, Zhu GH, Sengupta A, Hinkula J, et al · · 2022 · cited 45× · PMID 35450779 · DOI 10.1016/j.tibtech.2022.03.011
Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.
Ruan S, Huang Y, He M, Gao H. · · 2022 · cited 39× · PMID 35343112 · DOI 10.1002/advs.202200027
Immunotherapy for Prostate Cancer: Where We Are Headed.
Schepisi G, Farolfi A, Conteduca V, Martignano F, et al · · 2017 · cited 38× · PMID 29206214 · DOI 10.3390/ijms18122627
Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development.
Tabachnick-Cherny S, Pulliam T, Church C, Koelle DM, et al · · 2020 · cited 33× · PMID 32219902 · DOI 10.1002/mc.23190
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.
· 2018 · cited 23× · PMID 30400835 · DOI 10.1186/s40425-018-0422-y
Targeting the tumour cell surface in advanced prostate cancer.
Boixareu C, Taha T, Venkadakrishnan VB, de Bono J, et al · · 2025 · cited 12× · PMID 40169837 · DOI 10.1038/s41585-025-01014-w
Combating cancer immunotherapy resistance: a nano-medicine perspective.
Kong X, Xie X, Wu J, Wang X, et al · · 2025 · cited 5× · PMID 40207650 · DOI 10.1002/cac2.70025

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Sensei Biotherapeutics, Inc. trials

Trials by the same sponsor.

NCT04217720 — SNS-301 Monotherapy in High Risk MDS and CMML · Phase 2 · withdrawn
NCT04034225 — Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03120832 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sensei Biotherapeutics, Inc.
Last refreshed: 15 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03120832.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing